

# 2022

ANNUAL REPORT



CONQUERING THORACIC CANCERS WORLDWIDE

IASLC



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

Conquering Thoracic Cancers Worldwide

## CONNECT WITH US



**CONQUERING THORACIC CANCERS WORLDWIDE**



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Conquering Thoracic Cancers Worldwide

# TABLE OF CONTENTS

**04**

Welcome Letter

---

**05**

Membership

---

**08**

Scientific Affairs

---

**13**

Education & Conferences

---

**18**

Webinars

---

**20**

JTO & JTO CRR

---

**22**

IASLC Lung Cancer News

---

**24**

Podcasts

---

**26**

Committees

---

**30**

Patient Advocacy

---

**33**

Corporate Relations

---

**34**

IASLC Foundation, LLC

---

**39**

Financials

---

**40**

IASLC Board of Directors

---

**41**

IASLC Staff

---

# WELCOME

Dear colleagues and friends,

2022 was a mix of old and new for IASLC. We were thrilled to return to in-person events and equally excited to welcome our new CEO Karen Kelly and many wonderful new staff members. It was a year focused on providing as much benefit as possible for our members.

The ups and downs of the pandemic found our team quickly pivoting two planned in-person meetings into virtual ones, and still providing an outstanding experience for our members at TTLC and ELCC. We successfully returned to in-person events with WCLC in August with 3,348 attendees on-site in Vienna and another 1,837 joining us virtually. It was a phenomenal hybrid meeting. During the WCLC, we recognized the IASLC **Distinguished Service Awardees** and **Lecture Awardees** and hosted 5 plenary sessions, 39 education sessions, 15 oral sessions, 14 mini-oral sessions, 18 interactive breakfast sessions, and 8 workshops—including the 2022 CT Screening Symposium: Forefront Advances in Lung Cancer Screening. It was a whirlwind! Participants in our first IASLC STEPS Challenge, a virtual walkathon, stepped out to benefit the lung cancer research grant program. Many found a night of dancing at our foundation gala a great way to increase step counts.

We also successfully hosted the North America Conference on Lung Cancer in Chicago in September, where more than 550 participants from 25 countries, participated in person or remotely, to learn from 6 symposia, nearly 100 posters, and more than 100 abstract presentations. In October, the Asia Conference on Lung Cancer returned as a live and on-demand event. More than 500 delegates from 37 countries, learned from more than 110 speakers.

In 2022, we welcomed our new chief executive officer Dr. Karen Kelly, an internationally recognized and widely published lung cancer expert and former IASLC board member. She stepped down from her roles as a Professor at University of California, Davis, and as thoracic committee chair of SWOG to join the IASLC team full-time in Denver. Her experience and vision significantly enhance the organization. J. Michael Hoehn brought his considerable experience in business and nonprofits when he joined IASLC as the chief operating officer this year. He brings business management, strategic planning, and vision to the organization. In addition, we also added nine new staff members who are all eager to help meet the needs of our members.

Our publications also achieved success in 2022 with the **Journal of Thoracic Oncology** increasing its impact factor to 20.121, up from 15.069 last year—making it 4th of 66 respiratory journals and 13th of 245 oncology-specific journals. What's more, the JTO experienced a 1,704% increase in full-text article downloads in 2022.

We hired Dr. Emily Stone, from Australia to take over as Editor-in-Chief of the **Journal of Thoracic Oncology Clinical and Research Reports**, the IASLC's open-access companion journal, which publishes a range of manuscripts and was indexed in 2022 on PubMed Central. Dr. Stone took the helm in January 2023. Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St. Vincent's Hospital Sydney.

To support our efforts to provide the best value to our membership, we initiated a membership survey, the first since the pandemic. The survey asked members for feedback on member needs and benefits in the post-COVID world. More than 1,100 members from 77 countries shared their feedback. We are reviewing the input and will release a summary of these findings in 2023.

To support and fund emerging research in the field of thoracic lung cancer, the ILCF & IASLC Board of Directors transitioned the foundation to become a wholly owned entity of the IASLC with a new moniker, the IASLC Foundation, LLC. Its mission remains the same—to accelerate the pace of thoracic malignancy research and fund the next generation of lung cancer luminaries. In 2022, the Foundation received \$78,426 in individual donations. Please click [here](#) for the full list of our 2022 donors. The Foundation awarded 14 research grants totaling \$850,000. **This year's grant recipients represent** a diverse group of early-career researchers from around the world. IASLC Research Grants are made possible by donations from individual donors, foundation partners, and pharmaceutical companies and foundations.

Also this year we completed the data analysis for the 9th edition of the TNM Staging System and new recommendations from AJCC/UICC will be available to the public in 2024. For the first time, new data elements such as gene mutations, fusions, alterations, protein expression levels, and other critical tumor characteristics were collected for analysis. Work has already begun on the 10th edition.

And finally, members of our 13 IASLC committees contributed their skills and talents to help move the society forward by publishing multiple manuscripts, atlases, and other resources; supporting early-career and research grant recipients; leading workshops, webinars, surveys, and academies; and sharing the message of the organization with the larger lung and thoracic cancer communities.

As we head into 2023, we will be looking back at the 50-year history of IASLC with plans underway for a retrospective book so our members can appreciate how far we've come in the fight against thoracic cancers.

As we begin a new year, we believe this is an exciting time for IASLC as our members make unprecedented scientific advances and disseminate new knowledge to help prevent and treat thoracic malignancies worldwide. We hope you will continue to lend your expertise, knowledge, and enthusiasm to the fight.

Sincerely,



*Heather Wakelee, MD*  
Heather Wakelee, MD  
IASLC President



*Karen Kelly, MD*  
Karen Kelly, MD  
IASLC Chief Executive Officer



**DR. HEATHER WAKELEE, IASLC  
PRESIDENT, AND DR. KAREN KELLY,  
IASLC CEO, HIGHLIGHT THE SUCCESSES  
OF THE ORGANIZATION IN 2022**

# MEMBERSHIP

## TOGETHER, WE ARE CONQUERING LUNG CANCER WORLDWIDE

With a diverse multidisciplinary and international membership base, the IASLC is always looking for ways to listen to our members and improve the member experience. Because member feedback is critical to strategic planning initiatives, we conducted our first member survey since the COVID-19 pandemic. We received more than 1,000 responses from 77 countries, which provided critical information we need to plan future initiatives that build additional member value. Survey results will be shared with the membership soon.

IASLC members remain at the forefront of scientific achievement in multiple disciplines, and the IASLC seeks to continue to provide membership services that encourage more achievements in the future.

For more than four decades, IASLC members have led a worldwide movement to advance the mission of conquering thoracic cancers across the globe. In 2022, at events such as the World Conference on Lung Cancer (WCLC), the Asia Conference on Lung Cancer, the North America Conference on Lung Cancer, the IASLC CT Screening Symposium, and the Targeted Therapies of Lung Cancer Meeting, lung cancer specialists accessed the latest research and scientific discoveries in thoracic oncology, allowing them to advance their profession through education and development opportunities.

This year, the IASLC's focus was on returning to in-person events while also ensuring our colleagues across the globe had virtual access to important content. At WCLC in Vienna, many of our members were able to reconnect face-to-face for the first time since the pandemic and we remain hopeful for increased connections in 2023. Other meetings throughout the year emphasized reconnecting in person, allowing our members to share experiences and important information from their work in the field of thoracic cancer.

Comprising every specialty in lung cancer, IASLC committee members and their contributions are at the heart of the society. As part of our 13 committees, ranging from patient advocacy to scientific committees and more, IASLC committee members continue to contribute their specialized skills and talents to help shape the work of the organization, develop educational content, plan annual meetings, contribute to publications authored by the IASLC, and more.

The IASLC is always looking to improve the member experience and be the hub for education and collaboration for all of our members, regardless of career phase, specialty, or geographic location. As we move into 2023 with a new CEO, we will continue to enhance our value to members with our soon-to-be-released strategic plan.

The IASLC continues to put our members first—so they can go above and beyond for patients—by offering discounted registration fees to meetings and educational events, complimentary access to the *Journal of Thoracic Oncology* (JTO), and discounted publication fees for the open-access IASLC journal, *JTO Clinical and Research Reports* (JTO CRR). Another great member benefit is the IASLC Online Member Directory which allows members to directly connect and collaborate. In addition, the IASLC is proud to offer members access to free continuing medical education opportunities, volunteer opportunities, and more.




Access the IASLC member portal at [my.iaslc.org](https://my.iaslc.org)



MEMBERS CONQUERING THORACIC MALIGNANCIES WORLDWIDE

# IASLC MEMBERSHIP BY THE NUMBERS

## MEMBERS BY COUNTRY/REGION



## TOP 10 COUNTRIES FOR MEMBERSHIP



USA



JAPAN



CHINA



CANADA



AUSTRALIA



UK



BRAZIL



REPUBLIC OF KOREA




INDIA



NETHERLANDS


## MEMBERS BY GENDER




# 6,176

## MEMBERS TOTAL


## MEMBERS BY AGE




## LOCATION-PROFESSIONAL ACTIVITY/PRACTICE



## YEARS OF MEMBERSHIP



## MEMBERS BY PRIMARY SPECIALTY



\* Other includes: Pharmacy, Biostatistics, Smoking Cessation, Hematology, Resp. Therapy/Physiotherapy, Patient/Survivors, Caregivers and Unknown.

# SCIENTIFIC AFFAIRS



Every project that the IASLC dedicates itself to revolves around lung cancer research, across specialties and from around the globe. Whether that novel research is showcased in a new multi-day all-virtual symposium, a podcast or webinar with expert panelists who can put the data in context, or in an **IASLC Lung Cancer News** (ILCN) article that discusses the nuances of daily clinical application, we strive to support and promote practice-changing research, providing education to all of our volunteers and members.

## IASLC FLAGSHIP SCIENTIFIC PROJECTS | 2022

### Staging: Improving Lung Cancer Staging through International Collaboration

For more than 20 years, the IASLC Lung Cancer Staging Project has provided valuable recommendations for the TNM classification of lung cancer—jointly published by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The IASLC is currently analyzing data for the 9th edition of the TNM Staging System, which for the first time, will include new data elements such as gene mutations, fusions, number alterations, and protein expression levels. The goal of these additional tumor characteristics is to significantly enhance the accuracy of the Staging System, leading to more precise treatment regimens and increased patient survival.

Data collection for the 9th edition closed on December 31, 2021. In this edition, we collected the most data for any cycle of the TNM Staging Project, from more than 20 countries:

**124,541**

LUNG CANCER  
CASES

**4,585**

MESOTHELIOMA  
CASES

**11,316**

THYMIC  
MALIGNANCIES  
CASES

For the first time, the IASLC piloted a grant program for the Staging Project to provide funding for institutions located in low- to middle-income countries to submit data for the 9th edition. This funding allowed **16 institutions** from **12 countries** to contribute **9,739 total cases**. [Learn more](#) about the IASLC's Staging Project.

New TNM Staging Classification will be available in late 2023.

# IASLC FLAGSHIP SCIENTIFIC PROJECTS | 2022

## IASLC Atlas on Molecular Biomarker Testing for Targeted Therapy In Lung Cancer

The IASLC has produced several atlases dealing with a range of lung cancer biomarker testing topics including ALK, ROS1, EGFR, and PD-L1 and also an atlas on immunohistochemistry for lung cancer diagnosis. These atlases provide state-of-the-art, concisely presented information on clinical, pathological, and molecular testing aspects of the subject material in a user-friendly package.

The IASLC is working on a comprehensive atlas covering all current and emerging targets from both a diagnostic and clinical point of view. There will be dedicated chapters for each 'marker' – EGFR, ALK, ROS1, MET, KRAS, RET, NTRK, NRG, and HER2 – each written by pathologists and medical oncologists, covering both the therapeutic and the testing aspects relevant to each family of genomic alterations. The atlas will also cover a few broadly focused chapters covering various aspects of precision medicine in lung cancer—like specimen acquisition and the handling of tumor samples, the different available assays, and interpretation of results to reporting and quality assurance. This atlas aims to serve as a comprehensive, concise, and hands-on educational resource for multidisciplinary medical professionals. **The Molecular Atlas is available now.**

### The Molecular Atlas:

- Provides pathologists with “know-how” educational information on specimen acquisition (tissue and liquid), pre-analytical conditions, and molecular testing.
- Provides oncologists with the “know-why” educational information on how to interpret and potentially apply the results for a therapy where medically appropriate.
- Serves as an educational tool and hands-on resource for multidisciplinary medical professionals involved in precision medicine worldwide.

### Molecular Atlas Editors:



Lynette M. Sholl, MD



Ming-Sound Tsao, MD, FRCPC



Wendy A. Cooper, BSc (Med),  
MBBS, PhD, FRCPA



Keith M. Kerr, BSc, MBChB,  
FRCPath, Hon FRCPEd,  
Hon FRCSI



James Chih-Hsin Yang,  
MD, PhD



Daniel S.W. Tan, BSc (Hons),  
MBBS, MRCP

All IASLC Atlases & Resources can be [found here](#).

# IASLC FLAGSHIP SCIENTIFIC PROJECTS | 2022

## Pathologic Response (PR) Initiatives

Before undertaking the Pathologic Response (PR) project by the IASLC and the LAA, there were no established guidelines for processing and evaluating resected lung cancer specimens, and there was a lack of precise definitions for the degree of pathologic response following neoadjuvant therapy. These recommendations were published in the *Journal of Thoracic Oncology* in 2020.

The IASLC has nearly completed Phase 2 of the PR project, which aims to implement the IASLC recommendations by assessing a global cohort of pathologists' reproducibility of histological Major Pathologic Response (MPR) and Complete Pathologic Response (cPR) assessments in surgical resection specimens of lung cancer patients treated with neoadjuvant immune checkpoint inhibitors with and without chemotherapy. Each of these steps will help the IASLC establish PR, MPR, and/or cPR, in surgical resection specimens following neoadjuvant therapies as predictors and surrogate markers of long-term clinical benefit in patients with resected stage I to III lung cancer. Learn more about the [PR project](#).

### Phase 2: IASLC Reproducibility Study

The IASLC Reproducibility Study aims to determine reproducibility among pathologists of pathologic response determinations using the IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy. This study brings together an international cohort of 11 pathologists to evaluate 60-90 NSCLC tumors treated with anti-PD-1 or PD-L1 alone or in combination with chemotherapy or anti-CTLA-4 therapy. This study is ongoing and is expected to conclude in early 2023.

### Phase 2B: Digital Quantification of Pathologic Response in Neoadjuvant Treated Non-Small Cell Lung Cancer (NSCLC)

In this project, the IASLC will collaborate with PathAI to apply an AI-driven digital pathology assessment of pathologic response and compare this to manual assessments from the IASLC pathologic response interobserver study. This study will support the validation of an AI-powered assessment of pathological response. This project was conceptualized and fully funded in 2021 and is set to conclude in 2023.

### Phase 3: Lung Cancer Neoadjuvant Trial Endpoint Database (LCNTED)

In the final phase of the IASLC Neoadjuvant Therapies in Lung Cancer Initiative, a multidisciplinary group will identify the data necessary, collect the required information from neoadjuvant trials worldwide, and execute the statistical analyses to support the use of pathologic response as a determinant of long-term outcomes. This process has been accomplished in the CTNeoBC-pooled analysis project analyzing neoadjuvant trials in breast cancers.

Following the lead of CTNeoBC in breast cancers, Phase 3 of the LCNTED initiative will:

1. Establish the association between pathologic response and event-free survival (EFS) and overall survival (OS);
2. Establish the definition of pathologic response, including MPR and CPR, that correlates best with long-term outcomes;
3. Identify the lung cancer subtypes in which pathologic response best correlates with long-term outcomes; and
4. Assess whether increases in pathologic response between treatment groups predict improved EFS and OS.

An initiative of this magnitude and importance requires the collaboration of multiple partners and stakeholders to make meaningful progress. Therefore, this initiative will bring together the IASLC membership, FDA regulators, and various leading industry partners, who all share the common goal of eliminating lung cancer as a cause of death. The IASLC will begin database design in 2023, data collection as early as 2024, with the project concluding in 2028.



## Early Lung Imaging Confederation (ELIC)

The vision of the IASLC is to Conquer Thoracic Cancers Worldwide. One of the best ways to fulfill this vision, beyond risk reduction, is to detect cancers early. Effective low-dose computed tomography (LDCT) screening is critical to detecting and diagnosing lung cancer early and increasing survival. The Early Lung Imaging Confederation (ELIC) is an international alliance of collaborating individuals and institutions who share a vision to develop a globally distributed, privacy-secured, lung cancer imaging database and computational analysis environment. The fundamental goal of ELIC is to support the development of deep learning methods and artificial intelligence approaches to detect lung cancer and other diseases early using thoracic CT images, to characterize small pulmonary nodules and surrounding structures, and to measure responsiveness to therapeutic interventions. For more information about ELIC, please visit <https://iaslc-elic.org/>.


## COLLABORATING RESEARCHERS



**Stephen Lam, MD, FRCPC**  
British Columbia  
Cancer Research  
Vancouver, Canada



**Witold Rzyman, MD**  
Medical University of  
Gdansk  
Gdansk, Poland



**Kazuto Ashizawa, MD**  
Nagasaki University  
Nagasaki, Japan



**Ugo Pastorino, MD**  
IRCCS National Cancer  
Institute Foundation  
Milan, Italy



**Claudia Henschke, MD, PhD**  
Mount Sinai  
New York, NY, United States



**Annette McWilliams, MD**  
Fiona Stanley Hospital  
Perth, Australia



**Bruno Hochegger, MD, PhD**  
Federal University of Health  
Sciences of Porto Alegre  
Porto Alegre, Brazil



# EDUCATION & CONFERENCES

IASLC strives to provide quality education and networking opportunities to our members, and 2022 was no exception. We returned to in-person events with WCLC 2022 in Vienna followed by NACLC 2022 and ACLC 2022. Our members were excited to get to see and share information with each other face-to-face. However, we didn't leave all of our new-found expertise in hosting virtual events behind, as each event also had a virtual option. Some sessions were live-streamed for those who could not be there in person, and videos of the events were also made available on demand.

As we move forward into 2023, we plan to continue providing both in-person and virtual options for our events, allowing everyone working to defeat thoracic cancers and malignancies access to the latest information and education in the field.

## IASLC 2022 CONFERENCES AND EVENTS



FEBRUARY 22-26, 2022 | WORLDWIDE VIRTUAL EVENT

The IASLC 2022 Targeted Therapies of Lung Cancer Meeting took place February 22-26, 2022, as a worldwide virtual event. Meeting Chairs, **Drs. Paul A. Bunn, Jr., Roy Herbst, Lecia Sequist, Suresh Ramalingam, and Charu Aggarwal** welcomed more than **1,050 participants** from **47 countries** to share information about ongoing clinical trials of the newest therapies for lung cancer.

Participants were encouraged to actively participate in discussions and engage with industry supporters. Presenters summarized the data on relevant targets for new therapies and shared data on preclinical and early clinical data for each of the drugs directed against these targets. For TTLC 2022, 53 abstracts were submitted and 19 exhibitors and sponsors participated in the meeting, with Genentech as the Diamond sponsor.



**Open Questions Around First-line Treatment for EGFR Mutant Lung Cancers**

**EGFR TKI and chemotherapy**

TKI ALONE vs TKI WITH CHEMO

- To combine two active therapies, there needs to be improvement in PFS greater than the sum of sequencing AND/OR improvement in overall survival.
- EGFR TKI and chemotherapy combination therapy may further eradicate subclones that survive EGFR TKI monotherapy (PERSISTERS)
- Early studies demonstrate improvement in OS with the combination suggesting that further eradication of persister subclones changes natural history- longer time on treatment but also improved control throughout the disease course

Helena Yu MD

# IASLC 2022 CONFERENCES AND EVENTS

## IASLC 2022 World Conference on Lung Cancer

AUGUST 6-9, 2022 | VIENNA, AUSTRIA



The World Conference on Lung Cancer (WCLC 22) returned to an in-person format in 2022. Chairs **Drs. Robert Pirker, Eric Lim, Françoise Mornex, Silvia Novello, and Helmut Prosch** welcomed **5,185 attendees** from **103 countries**. The event included a virtual component with all plenary sessions live-streamed and all sessions available online within 24 hours.

There was plenty for attendees to learn in the 5 plenary sessions, 39 education sessions, 15 oral sessions, 14 mini-oral sessions, 18 interactive breakfast sessions, and 8 workshops. In addition, 1,469 abstracts were submitted in 2022, with 1,119 accepted. For those interested in imaging advances, the CT Screening Symposium took place in person as a pre-conference event.

### Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene-Driven NSCLC

The International Association for the Study of Lung Cancer, Chinese Society for Clinical Oncology, and the Chinese Alliance Against Lung Cancer presented outstanding educational and cutting-edge research during this on-demand session at the 2022 World Conference on Lung Cancer. **Drs. Yi-Long Wu, Chunxue Bai, Caicun Zhou, and Karen Kelly** presented research and global perspectives on Liquid Biopsy in Oncogene-Driven NSCLC, as well as three oral abstract presentations and a discussion of 10 posters based on research performed by our Chinese colleagues.

### WCLC 2022 AWARD WINNERS

Each year, the IASLC honors professionals who have made major contributions to the field of thoracic cancers with its Distinguished Service Awards. The association distributes awards that recognize lifetime achievement in specific areas of practice, with the most significant honors—the **IASLC Distinguished Service Awards**—being distributed during the WCLC Opening Ceremony.

 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER <b>MARY J. MATTHEWS</b> PATHOLOGY/TRANSLATIONAL RESEARCH AWARD  <b>RAFAEL ROSELL</b> MD, PhD SPAIN	 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER <b>THE ADI F. GAZDAR</b> IASLC MERIT AWARD  <b>VALERIE RUSCH</b> MD UNITED STATES	 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER <b>PAUL A. BUNN, JR.</b> SCIENTIFIC AWARD  <b>JAMES YANG</b> MD, PhD TAIWAN	 INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER <b>JOSEPH W. CULLEN</b> PREVENTION/EARLY DETECTION AWARD  <b>EDWARD PATZ</b> MD UNITED STATES
--	---	--	---

HEAR OUR VOICES

DR. ANDRES RIMNER DISCUSSES THE VALUE OF IASLC EXCLUSIVE CONTENT AT ITS CONFERENCES AND OTHER EDUCATIONAL EVENTS

# 2022 LECTURESHIP AWARDS

During WCLC 2022, the IASLC presented Lectureship Awards to clinicians and researchers who made significant contributions to the fight against lung cancer. The awards represent major categories of lung cancer research, from tumor staging to tobacco control and smoking cessation. The 2022 IASLC Lectureship Awards winners include:



ROBERT J. GINSBERG LECTURESHIP AWARD  
FOR SURGERY  
Isabelle Opitz, MD  
University Hospital Zurich  
Zurich, Switzerland  
Thoracic Surgery



CLIFTON F. MOUNTAIN LECTURESHIP AWARD  
FOR STAGING  
Clarissa Mathias, MD, PhD  
NOB Oncoclinicas, Salvador  
Bahia, Brazil  
Oncology



IASLC LECTURESHIP AWARD FOR  
TOBACCO CONTROL AND SMOKING CESSATION  
Ray Osarogiagbon, MD  
Baptist Cancer Center  
Memphis, Tennessee  
Thoracic Oncology



JAMES D. COX LECTURESHIP AWARD  
FOR RADIATION ONCOLOGY  
Yuko Nakayama, MD  
National Cancer Center  
Tokyo, Japan  
Radiation Oncology



FRED R. HIRSCH LECTURESHIP AWARD  
FOR TRANSLATIONAL RESEARCH  
Lukas Bubendorf, MD  
University Hospital  
Basel, Switzerland  
Surgical Pathology



TSUGUO NARUKE LECTURESHIP AWARD FOR SURGERY  
Wenzhao Zhong, MD, PhD  
Guangdong Provincial People's Hospital and Guangdong  
Academy of Medical Science  
Guangzhou, Guangdong, China  
Surgery



DANIEL C. IHDE LECTURESHIP AWARD  
FOR MEDICAL ONCOLOGY  
Patrick Forde, MD, MBChB  
Johns Hopkins Hospital  
Baltimore, Maryland  
Oncology



IASLC LECTURESHIP AWARD FOR NURSES  
AND ALLIED HEALTH PROFESSIONALS  
Anne Fraser, NP  
Lung Foundation NZ  
Auckland, New Zealand



HEINE H. HANSON LECTURESHIP AWARD  
FOR SMALL CELL LUNG CANCER  
Stephen Liu, MD  
Lombardi Comprehensive Cancer Center  
Georgetown University  
Washington, D.C.  
Thoracic Oncology

Learn more about the IASLC's [Distinguished Service Award Winners](#), [Lectureship Award Winners](#), and [Advocacy Winners](#).



# 2022 World Conference on Lung Cancer

AUGUST 6-9, 2022 | VIENNA, AUSTRIA

## QUICK FACTS

NUMBER OF INVITED SPEAKERS

**324**

FEATURED & E-POSTERS

**970**

EDUCATION AWARDS

**10x**  
EARLY  
CAREER

**9x**  
DEVELOPING  
NATIONS

NUMBER OF PLENARY SPEAKERS

**26**

DISCUSSANTS

**51**

**4x**  
NURSE/  
ALLIED HEALTH  
PROFESSIONAL

**3x**  
PATIENT  
ADVOCATE  
EDUCATION

INVITED SESSION CHAIRS

**199**

## OTHER FIGURES

**5,185**

DELEGATES

**66.5**

CME CREDITS  
OFFERED

**38**

EXHIBITORS

**\$100,000**

RAISED FOR  
INTERNATIONAL LUNG CANCER  
FOUNDATION\*

**103**

COUNTRIES

**47**

LIVE Q&A PANEL  
DISCUSSIONS

**18**

SYMPOSIUM

\*(includes Benefit Event  
& STEPS Challenge)

## GLOBAL MEDIA COVERAGE

**42**

NEWS RELEASES ISSUED

**120**

REGISTERED  
JOURNALISTS

**65,600**

TOTAL MEDIA MENTIONS

**131**

TOTAL NUMBER OF  
COUNTRIES IN WHICH  
MEETING WAS COVERED

**38**

SCIENTIFIC  
RELEASES

**8**

AWARDS  
RELEASES

**831**

UNIQUE MEDIA OUTLETS

**17,585**

VIEWS OF IASLC  
NEWS RELEASES  
ON EUREKALERT BY  
JOURNALISTS

**4**

PRESS BRIEFINGS

# IASLC 2022 CONFERENCES AND EVENTS

## IASLC | IASLC 2022 CT SCREENING SYMPOSIUM: FOREFRONT ADVANCES IN LUNG CANCER SCREENING AUGUST 6, 2022 | VIENNA, AUSTRIA

The CT Screening Symposium was a one-day, immersive, in-person event featured at WCLC 2022 focused on lung cancer screening technologies and best practices. Using a mix of live educational presentations, real-time expert discussions, and interactive live Q&A opportunities, the Symposium addressed topics relevant to our international audience. Faculty provided anecdotal experience and reviewed current data highlighting successes and addressing barriers to implementing more uniform and effective lung cancer screening worldwide.



## IASLC | 2022 North America Conference on Lung Cancer SEPTEMBER 23-25, 2022 | CHICAGO, IL, USA

NALC 2022 offered myriad opportunities for networking and education for attendees. The meeting focused on the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. Chairs **Drs. Jessica Donington, Marina Garassino, and Jyoti Patel** created an event that met the needs of both our in-person attendees and our virtual ones.

The event hosted **568 attendees** from **25 countries**. We had 65 chairs and speakers and 19 sponsors and exhibitors. Attendees learned from 6 symposia, 89 posters, and 108 abstracts.

## IASLC | IASLC 2022 Asia Conference on Lung Cancer OCTOBER 27-29, 2022 | NARA, JAPAN

ACL 2022 returned this year with an in-person meeting in Nara, Japan. The conference highlighted the latest research in the field of thoracic cancer and malignancies while providing plenty of opportunity for face-to-face networking. Chaired by **Drs. Tetsuya Mitsudomi, Myung-Ju Ahn, and James CH Yang**, the event brought together experts working in a variety of disciplines to facilitate a shared knowledge base across the specialty.

The conference hosted **511 attendees** representing **37 countries**. Attendees heard from 111 speakers and interacted with 9 sponsors and exhibitors. Research and information was shared through 7 symposia, 118 posters, and 167 abstracts. ACL 2022 was the first international meeting to take place at the Nara Convention Center since the pandemic began.



Looking ahead to 2023, the IASLC is committed to maintaining our high-quality education to ensure our members have the necessary resources to eradicate lung cancer and other thoracic malignancies worldwide. IASLC continues to monitor the COVID-19 pandemic and public safety and will continue to offer in-person and digital meeting options for most of our 2023 IASLC programs. It is a primary goal that the IASLC continues to be the leader in lung cancer and thoracic oncology education, by providing practice-impacting education and networking opportunities to advance groundbreaking research to its membership.

# WEBINARS

Webinars are an important part of IASLC's offerings, providing education and insight to those in the thoracic cancer community. In 2022, 686 people attended IASLC webinars, representing multiple specialties, geographical regions, and both IASLC members and non-members.

## 2022 IASLC Webinars

### January - Updates on Liquid Biopsy for Advanced NSCLC: A Consensus Statement from the IASLC

There have been major advancements in therapies and diagnostics for advanced-stage non-small cell lung cancer over the past few years and these have led to meaningful increases in survival. One of the biggest advances is in therapeutics and diagnostics for molecular alterations that drive the oncogenic process. Tumor tissue has been the accepted standard biospecimen but there can be limitations with tissue, including collection and analysis. Thus, liquid biopsy, primarily blood plasma, represents a practical alternative source for determining tumor-derived somatic alterations.

*Faculty: Dr. Christian Rolfo, Dr. David Gandara and Dr. Natasha B. Leighl*

### April - Emerging Perioperative Treatment Using Immune Checkpoint Inhibitors in Patients with Resectable NSCLC

Immune checkpoint inhibitors and EGFR-TKIs, which have shown efficacy in advanced lung cancer, are now being applied to perioperative treatment. Many agents are expected to be introduced into the perioperative treatment of resectable Stage IB to Stage III, but the balance of efficacy and adverse events varies for each subset of patients. In using each agent in clinical practice, the debate continues as to whether a new perioperative therapy should be recommended for all patients or for a subset of patients. In this webinar, we strove to deepen the discussion on immune checkpoint inhibitors in the perioperative setting.

This was a joint webinar between IASLC and JLCS (Japan Lung Cancer Society, <https://www.haigan.gr.jp/>).

*Moderators: Dr. Hidehito Horinouchi & Dr. Tetsuya Mitsudomi*

*Speaker: Dr. Enriqueta Felip*

*Panelists: Dr. Tasushi Yatabe, Dr. Hirotsugu Kenmotsu and Dr. Yasuhiro Tsutani*

### August – American Society of Clinical Oncology (ASCO 2022) Meeting Highlights

This one-hour live session synthesized lung cancer research presented at the June 3-7 live meeting of the American Society of Clinical Oncology (ASCO). It addressed physicians' need to keep abreast of current research and future trends to inform clinical practice.

*Moderator: Dr. Antoinette Wozniak*

*Presenters: Dr. Shirish M. Gadgeel and Dr. Karen Reckamp*

### October – IASLC-STARS Webinar: Real-World Data (RWD) Leading to Real-World Evidence (RWE)

This one-hour session highlighted real-world data leading to real-world evidence. The webinar was hosted by the Research Advocacy Network (RAN) and was presented in English. The webinar was also translated into Spanish, German, Dutch, and French.

*Moderator: Janet Freeman-Daily*

*Presenters: Dr. Bellinda King-Kallimanis and Dr. Upal Basu-Roy*

### November - ESMO 2022 NSCLC Highlights

This one-hour live session synthesized lung cancer research presented at the September 9-13 meeting of the European Society for Medical Oncology (ESMO). It addressed physicians' need to keep abreast of current research and future trends to inform clinical practice.


*Moderator: Dr. Nicolas Girard*

*Presenters: Dr. Lizza Hendriks and Dr. Jordi Remon*



# 2022 TOTAL WEBINAR DATA

## ATTENDEES BY PRIMARY SPECIALTY



# 686

## TOTAL ATTENDANCE



Physicians\*



Non-physicians\*




Members

\*Based on 2 webinars


**CLICK  
TO ACCESS  
RECORDED  
WEBINARS**

## ATTENDEES BY CONTINENT



# JTO & JTO CRR

PROVIDING IMPACTFUL AND ACCESSIBLE RESEARCH FOR THE LUNG CANCER COMMUNITY



**JTO**  
Impact Factor\*  
increases to  
**20.121!**

## JOURNAL OF THORACIC ONCOLOGY

The *Journal of Thoracic Oncology* (JTO), the IASLC's official journal, is the authoritative publication for education and information related to all aspects of thoracic malignancies. The JTO includes original research, reviews, and opinion pieces, and reaches a diverse audience, including epidemiologists, statisticians, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.

The JTO's impact factor,\* a measure of its influence on the field, has climbed dramatically in recent years. The 2021 impact factor for JTO is 20.121 up from 15.609 in 2020. This moves the journal's rank to 4th among 66 respiratory medicine journals and 13th among 245 oncology journals.

“It is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 20.121, JTO is the leading journal in thoracic oncology and in the top fifteen (ranked 13th) of all cancer journals. JTO's emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field.”



-Alex A. Adjei, MD, PhD  
Editor-in-Chief

## J T O R A N K I N G S :

ONCOLOGY JOURNALS      RESPIRATORY JOURNALS

**13** OUT OF **245** IN 2021  **4** OUT OF **66** IN 2021

## JTO MOST CITED ARTICLES PUBLISHED IN 2022

Citations (2022)	Article Title	Authors
105	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015	Nicholson A.G., Tsao M.S., Beasley M.B., Borczuk A.C., Brambilla E., et al.
54	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial	Paz-Ares L.G., Ramalingam S.S., Ciuleanu T.-E., Lee J.-S., Urban L., et al.
45	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status	Ricciuti B., Arbour K.C., Lin J.J., Vajdi A., Vokes N., et al.
40	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain	Nogami N., Barlesi F., Socinski M.A., Reck M., Thomas C.A., et al.
34	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial	Lu S., Wang Q., Zhang G., Dong X., Yang C.-T., et al.
33	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?	Marx A., Chan J.K.C., Chalabreysse L., Dacic S., Detterbeck F., et al.
31	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC	Wu Y.-L., John T., Grohe C., Majem M., Goldman J.W., et al.
27	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses	Gounant V., Ferre V.M., Soussi G., Charpentier C., Flament H., et al.
26	Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (Camel-Sq): A Phase 3 Trial	Ren S., Chen J., Xu X., Jiang T., Cheng Y., et al.
25	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis	Planchard D., Besse B., Groen H.J.M., Hashemi S.M.S., Mazieres J., et al.

(Source: Elsevier)

# JTO & JTO CRR

## PROVIDING IMPACTFUL AND ACCESSIBLE RESEARCH FOR THE LUNG CANCER COMMUNITY

### JTO CLINICAL AND RESEARCH REPORTS

**JTO Clinical and Research Reports** (JTO CRR) transitioned to article-based publishing and became a monthly publication in 2021. In just 10 short months, JTO CRR was indexed in PubMed Central. The journal is now in the process of application to be evaluated and to enter the Emerging Source Citation Index (ESCI), part of the Web of Science core collections. (The journal will receive an impact factor a year after being indexed in ESCI).

Dr. Emily Stone, MBBS, PhD, FRACP officially took the reins as the Editor-in-Chief of JTO CRR on January 9, 2023, as Dr. Alex Adjei steps down from the role. Dr. Stone is a consultant respiratory physician and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St. Vincent's Hospital Sydney. The editorial teams are excited for the next chapter under Dr. Stone's editorial leadership and strategic stewardship of JTO CRR.



JTO CRR's success and continued growth are a reflection of the support of our readers, authors, and reviewers. This open-access journal broadens the reach of the IASLC throughout the world, offering unfettered access to the thoracic oncology community.

### JTO CRR MOST CITED ARTICLES, 2022

Citations (Lifetime)	Article Title	Authors
22	Catalog of 5' fusion partners in RET+ NSCLC Circa 2020	Ou S.-H.I., Zhu V.W.
16	EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors	Vasconcelos P.E.N.S., Gergis C., Viray H., Varkaris A., Fujii M., Rangachari D., VanderLaan P.A., Kobayashi I.S., Kobayashi S.S., Costa D.B.
15	A Catalog of 5' Fusion Partners in ROS1-Positive NSCLC Circa 2020	Ou S.-H.I., Nagasaka M.
9	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review	Zhu V.W., Nagasaka M., Madison R., Schrock A.B., Cui J., Ou S.-H.I.
9	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC	Miyawaki T., Naito T., Kodama A., Nishioka N., Miyawaki E., Mamesaya N., Kawamura T., Kobayashi H., Omori S., Wakuda K., Ono A., Kenmotsu H., Murakami H., Notsu A., Mori K., Harada H., Endo M., Takahashi K., Takahashi T.
6	Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study	Fujimoto N., Okada M., Kijima T., Aoe K., Kato T., Nakagawa K., Takeda Y., Hida T., Kanai K., Hirano J., Ohe Y.
4	Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria—Reducing Race Disparities	Pasquinelli M.M., Tammemagi M.C., Kovitz K.L., Durham M.L., Deliu Z., Rygalski K., Liu L., Koshy M., Finn P., Feldman L.E.
4	Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study	Pujol J.-L., Vansteenkiste J., Paz-Ares Rodriguez L., Gregorc V., Mazieres J., Awad M., Janne P.A., Chisamore M., Hossain A.M., Chen Y., Beck J.T.
4	Utility of Newly Proposed Grading System From International Association for the Study of Lung Cancer for Invasive Lung Adenocarcinoma	Kagimoto A., Tsutani Y., Kambara T., Handa Y., Kumada T., Mimae T., Kushitani K., Miyata Y., Takeshima Y., Okada M.
3	Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report	Begum P., Goldin R.D., Possamai L.A., Popat S.

(Source: Scopus)

# THE IASLC LUNG CANCER NEWS



The **IASLC Lung Cancer News (ILCN)** is the IASLC's official news source for thoracic oncology specialists around the globe. ILCN provides its international audience with timely and relevant lung cancer news on topics across specialties and interests, including medical, radiation, and surgical oncology, as well as patient advocacy, nursing and allied health, and pathology. Led by Editor Dr. Corey Langer, ILCN is filled with nuanced expert perspectives on topics that span the lung cancer care continuum, from screening through survivorship to end-of-life conversations.



With new content posted to **ilcn.org** every two weeks, readers will regularly find content applicable to their specialty and interests. A twice-monthly digital edition is delivered directly to the inboxes of all IASLC members.

For more information about ILCN's editorial group, visit:  
<https://www.iaslc.org/iaslc-news/ilcn-editorial-group>

## THE VOLUNTEERS WHO MAKE ILCN POSSIBLE



EDITOR  
 Corey J. Langer, MD, FACP  
 USA



ASSOCIATE EDITOR  
 Fabrice Barlesi, MD, PhD  
 France



ASSOCIATE EDITOR  
 Caicun Zhou, MD, PhD  
 China



D. Ross Camidge, MD



Edgardo S. Santos  
 Castillero, MD, FACP



José Francisco  
 Corona Cruz, MD



Anne-Marie C.  
 Dingemans, MD, PhD



Ivy Elkins  
 Patient Advocate



Mary Jo Fidler, MD



Shirish Gadgeel, MD



Bruno Hochegger,  
 MD, PhD



Angus Pratt, MBA  
 Patient Advocate



Karen Reckamp, MD



Christian Rolfo, MD,  
 PhD, MBA



Witold K. Rzyman, MD



Ricardo Sales dos  
 Santos, MD, PhD



Joan Schiller, MD



Suresh Senan, MD



Brendon Stiles, MD



Aaron Tan, MD



Ricardo Terra, MD,  
 PhD, MPH



Murry Wynes, PhD



Erin Jungmeyer  
 Managing Editor



Jan Mazotti  
 Staff Liaison

# THE IASLC LUNG CANCER NEWS

## BY THE NUMBERS

In 2022, ILCN received **154,240** unique page views by **86,180** users that cover the globe. The top 10 countries represented by ILCN's 80,000+ readers are:



USA



CHINA



UK



INDIA



CANADA



JAPAN



ITALY



TAIWAN



NETHERLANDS



GERMANY


## THE TOP 10 MOST-READ ILCN ARTICLES OF 2022

1. **Comments on 8th Edition of TNM Classification of Lung Cancer** (Read 5,362 times)
2. **A Holistic Approach to Patient Care** (Read 5,187 times)
3. **Lung Cancer in Never-Smokers: An Epidemiologic Perspective** (Read 4,165 times)
4. **Valuable Intersections: Maximizing Career Opportunities Arising From the Relationship Between Academia and Industry** (Read 3,115 times)
5. **Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates** (Read 2,531 times)
6. **Controversy Regarding U.S. Marketing of New Heated Tobacco Product IQOS** (Read 2,386 times)
7. **Alternative Dosing Strategies for Immune Checkpoint Inhibitors** (Read 2,355 times)
8. **A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?** (Read 1,759 times)
9. **Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients** (Read 1,641 times)
10. **CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients with Lung Cancer** (Read 1,372 times)

### Comments on the 8th Edition of the TNM Classification of Lung Cancer

By: Fabrice Barlesi, MD, PhD and Eric Vallières, MD, FRCSC  
on August 01, 2022

PRINT EMAIL



### A Holistic Approach to Patient Care

By: Lauren Evoy Davis  
on January 21, 2022

NEBRASKA HEALTH | WCLC 2020 ARCHIVE

PRINT EMAIL

#### Key Results: Multifactorial Assessment

- Average CARG-CGA score 7.54 (SD=2.85, range=0-12)  
Moderate risk of chemo toxicity
- Average SPPB score 8.67 (SD=3.20, range=0-12)  
One or more mobility limitations
- Timed Up and Go test 24 (48%) no fall risk (<10 sec)  
15 (36%) mild fall risk (10-20 sec)
- 82% independence with ADLs (dress, toilet, walk, eat)
- M baseline disability score 2.67 (SD=2.85, range=1-13)  
Mild disability in usual activities, self-care, and/or mobility
- Average PROMIS-10 score 34.6 (SD=7.02, range=19-49)  
1.5 standard deviations below quality of life of general population

SHARE


Treating the whole patient, not just the disease, is a basic emotional, and spiritual needs of patients can help providers comes in many forms, and some patients need help build

### Lung Cancer in Never-Smokers: An Epidemiologic Perspective

By: Daniel S.W. Tan, MD, PhD and Chee-Keong Toh, MD  
on February 03, 2022

GLOBAL INITIATIVES

PRINT EMAIL



### Valuable Intersections: Maximizing Career Opportunities Arising From The Relationship Between Academia and Industry

FOR DR. JEAN-CHARLES SORIA, THE OPPORTUNITY TO MAKE SCIENCE ACTIONABLE AND INCREASE ITS IMPACT DROVE HIS DECISION TO WORK IN INDUSTRY.

By: Jean Charles Soria, MD, PhD  
on April 05, 2022

NEBRASKA NEWS

PRINT EMAIL

### Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates

RESEARCHERS SAY INCREASED SCREENING OF AT-RISK POPULATIONS, INCLUDING THOSE WHO HAVE NEVER SMOKED, MAY IMPROVE SURVIVAL. MORE THAN ANY OTHER STRATEGY.

By: Pan-Chyr Yang, MD, PhD, Gwei-Chen Chang, Chao-Hua Chiu, MD, and Chong-Jen Yu, MD, PhD  
on June 01, 2022

EVOLVING STANDARDS OF CARE | INDUSTRY NEWS & REGULATORY APPROVALS

PRINT EMAIL


The incidence of lung cancer among people who have never smoked is increasing globally. It is estimated that 10% to 25% of lung cancer patients worldwide never smoked. Lung cancer in this subset of patients is more prevalent in East Asia, especially in women.<sup>1,2</sup>

In Taiwan, we implemented a stop-smoking campaign in 1995, and the smoking rate in adult males has since decreased from 55% to 23%. The smoking rate in adult women remained stable at about 3%. However, the incidence of lung cancer—especially non-small cell lung cancer (NSCLC) and adenocarcinoma subtype (Fig. 1)—keeps rising in both men and women.



Pan-Chyr Yang, MD, PhD

# LUNG CANCER CONSIDERED



with **Dr. Stephen Liu** and **Dr. Narjust Florez**  
an IASLC Podcast

Tune in to Lung Cancer Considered, the official IASLC podcast, for conversations with the researchers, healthcare professionals, patients, and advocates who make a difference in treating thoracic cancers.



During 2022, listenership of the podcast surpassed 100,000 listeners, and the podcast won the w3 Gold Award for creative excellence.

Lung Cancer Considered also began streaming on Apple Podcasts and Spotify, as well as SoundCloud during 2022.



**Listen here and join the conversation.**




**LUNG CANCER CONSIDERED:  
GLOBAL CONVERSATIONS  
THAT MATTER WITH  
DRS. STEPHEN LIU &  
NARJUST FLOREZ**

Lung Cancer Considered was funded in part by AstraZeneca, Bristol Myers Squibb, Lilly Oncology, and Merck KGaA.

# 2022 TOTAL PODCAST DATA

## LISTENS BY YEAR



**130,615**  
ALL-TIME LISTENS

## TOP COUNTRIES



UNITED STATES - 79,955



AUSTRALIA - 8,236



JAPAN - 6,580

## MOST USED WEBSITES, RSS AND THIRD-PARTY APPS



www.iaslc.org **6,018**

AppleCoreMedia iPhone **11,381**

RSS Feed **113,118**



## TOP 10 PODCASTS IN 2022

Title of Podcast	Total Listens
ASCO 2022 Highlights	1,717
WCLC 2022 Daily Highlights	1,687
Overview of EGFR in NSCLC	1,547
Targeting ALK in NSCLC	1,520
Virtual Tumor Board: EGFR Mutant NSCLC	1,377
TTLC 2022 Highlights	1,365
Antibody Drug Conjugates (ADCs) in NSCLC	1,330
Climate Change & Lung Cancer: Part One	1,294
Targeting NTRK in NSCLC	1,278
Virtual Tumor Board: Advanced PD-L1 negative NSCLC	1,272


# COMMITTEES 2021-2023

Volunteers are the heart of IASLC committees as each member contributes their specialized skills and talents to help define the work of the organization, develop educational content, shape the association’s messaging, plan annual meetings, contribute to IASLC publications, and more.

Each committee reports to the IASLC Board of Directors and has a chair (or co-chairs), a board liaison, and a staff liaison. Committee members are currently in the middle of their 2021-2023 term, and each committee was carefully selected to ensure relevant expertise, as well as diversity by region and gender.

## Advanced Radiation Technology (ART) Committee

Members of the ART committee have planned multiple educational webinars and podcasts, published extensively in the JTO, and collaborated with other radiation oncology societies to develop new guidelines and content this year, including **“Avoiding Toxicity with Lung Radiation Therapy: An IASLC Perspective”** in May 2022. **Dr. Fiona McDonald** of The Royal Marsden Hospital in the United Kingdom is the Committee Chair.



This figure describes the evolving evidence supporting the use of IMRT/VMAT over 3D CRT techniques to reduce toxicity and improve the chance of completing the prescribed treatment course. 3D CRT, three-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy.



## Career Development & Fellowship Committee

The Career Development and Fellowship Committee focuses on providing support for the next generation of lung specialists by awarding research grants. The committee reviews and scores grant applications and **selects grant recipients**. **Dr. Ahmed Rabea** of the National Cancer Institute of Egypt is the committee chair. In 2022, the Committee reviewed 91 applications and selected 14 recipients, awarding grants totaling \$850,000.

## Communications Committee

The Communications Committee develops campaigns to increase IASLC brand recognition and credibility while educating the public about complex lung and thoracic cancer issues. In addition, the committee chooses articles from the **Journal of Thoracic Oncology** to promote to the media to enhance public understanding of lung and thoracic cancer. Through press releases, **Lung Cancer Considered** podcasts, and **ILCN** articles, Communications Committee members work to enhance the visibility of IASLC on an international stage and provide IASLC members, the thoracic oncology community at large, and the media with accurate and timely perspectives on hot topics in lung cancer. At WCLC 2022, members of the Communications Committee offered a social media and communications workshop, where attendees learned from lung cancer influencers how to work with communications teams, build a personal brand, promote research and advocacy through traditional and social networks, give the perfect interview, and engage in the Latin American and Asian markets. **Dr. Brendon Stiles** of the Montefiore-Einstein Cancer Center in New York is the committee chair.



IASLC 2022 Communications Committee.



**DR. BRENDON STILES & DR. JARUSHKA NAIDOO: COMMUNICATIONS COMMITTEE IS DELIVERING EDUCATION THROUGH NEW METHODS**

# COMMITTEES 2021-2023

## Continuing Medical Education Committee

In 2022, the IASLC was granted another four years as an ACCME CME Provider. The CME Committee ensures that all accredited activities meet the ACCME Accreditation Requirements, including the ACCME Standards for Integrity and Independence in Accredited Continuing Education<sup>SM</sup>. The CME Committee also makes sure that IASLC CME activities meet the requirements of the American Medical Association Physician's Recognition Award (AMA PRA). **Dr. Apar Kishor Ganti** of the University of Nebraska Medical Center and **Dr. Nick Pavlakis** of the Royal North Shore Hospital in Australia co-chair the committee.



IASLC 2022 Academy led by members of the Education Committee.

## Education Committee

The Education Committee lives out IASLC's mission to provide education and information about lung cancer and other thoracic malignancies to IASLC members, the medical community at large, and the public. The committee works to identify educational needs and practice gaps, develop learning objectives, design accredited and non-accredited educational programs, and evaluate the effectiveness of IASLC educational activities. The Education Committee and the Continuing Medical Education committee work together to ensure activities meet the IASLC CME Mission and are implemented in compliance with ACCME. **Dr. Christian Rolfo** of the Tisch Cancer Institute at Mount Sinai in New York is the committee chair.



## Membership Committee

In 2022, as part of its responsibilities, the Membership Committee assisted IASLC staff with the 2022 Member Survey, which provided valuable insight into our members and their needs. The committee members also helped to plan the Committee Corner at WCLC 2022 along with their regular duties of reviewing and recommending membership status requirements and benefits for all IASLC members. The committee sets strategy and implements tactics to increase and retain association membership across specialties and regions. The committee focuses on sharing the message of the IASLC and ensures the benefits it offers are a great value for thoracic oncology professionals and fosters relationships with new members from around the globe. **Dr. Nan Wu** of Peking University Cancer Hospital & Institute in China is the committee chair.



IASLC 2022 Membership Committee.



**DRS. GALATEAU-SALLE & OPITZ SHARE MORE ABOUT THE WORK OF THE IASLC MESOTHELIOMA COMMITTEE**

## Mesothelioma Committee

The Mesothelioma Committee seeks to accelerate the pace of research and work across geographies to develop strategic research goals and to bring the disease to the forefront of research. In 2022, the committee organized a joint workshop at WCLC 2022 to share the outlook on the future of mesothelioma treatment, including new drugs, pathological and biological breakthroughs, and educational panel discussions with leaders in the field. Several research updates in mesothelioma in recent years have been spearheaded by members of the Mesothelioma Committee. The committee is chaired by **Dr. Paul Baas** of The Netherlands Cancer Institute.

# COMMITTEES 2021-2023

## Nursing & Allied Health Professionals Committee

The Nursing & Allied Health Professionals Committee (NAHP), composed of multidisciplinary clinicians and researchers each with a unique perspective, is committed to advancing the education of both practitioners and patients in thoracic oncology. The committee's goal is to improve and optimize outcomes for oncology patients and families across the cancer trajectory through diagnosis, treatment, survivorship, and end-of-life. In 2022, the NAHP Committee collaborated with ITONF at WCLC 2022 to host a workshop featuring global leaders discussing targeted therapies in NSCLC; addressing symptom management, palliative care, & survivorship; unlocking the secrets of immunotherapy; addressing stigma & shame; working across borders, and more. **Dr. Maria Ftanou** of Peter MacCallum Cancer Center in Australia is the committee chair.



## Pathology Committee



IASLC 2022 Pathology Committee.

The Pathology Committee helps fulfill core aspects of IASLC's mission, including producing publications, such as the **IHC Atlas**, offering guidance for the organization's annual slate of meetings, and helping to establish the IASLC as an international leader in the clinical and scientific aspects of lung cancer pathology. During 2022, the Committee authored and published three pioneering JTO articles including:

- **Defining morphologic features of invasion in pulmonary non-mucinous adenocarcinoma with lepidic growth – A proposal by the IASLC Pathology Committee**
- **Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee**
- **NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma**

This team is also instrumental in the IASLC's Pathologic Response Initiatives and the research and publication of the Molecular Atlas. **Dr. Wendy Cooper** of the Royal Prince Alfred Hospital in Australia chairs the Pathology Committee.

## Patient Advocates Committee

The Patient Advocates Committee addresses the direct impact research has on its beneficiaries—patients with lung cancer—and how they can support continued research to improve treatment options and availability. In 2022, the committee launched the Patient Advocacy Survey to determine how IASLC has been meeting patient advocate needs and how we can make improvements in the future. The survey was sent to IASLC members who identify as patient advocates and was also made available to the general public. Once analyzed, the survey results will help make sure IASLC offerings for patient, survivor, and caregiver/partner members are effective and reach their intended users. The committee also explored collaboration opportunities to create patient guides and resources, including patient-friendly research summaries. Members also revamped the Education Awards and Cancer Care Team Award and collaborated with other IASLC committees, providing input and a patient advocacy perspective to other focus areas. **Jill Feldman** of EGFR Resisters chairs the Patient Advocates Committee.



# COMMITTEES 2021-2023


## Screening and Early Detection Committee

The IASLC Screening and Early Detection Committee is a multi-disciplinary group dedicated to advancing screening and early detection programs through education and research across the globe. Committee members include leaders from radiology, thoracic surgery, pulmonary medicine, medical oncology, nursing, basic science, and advocacy organizations from North America, Europe, Asia, and South America.

**Dr. Stephen Lam** of the BC Cancer Center in Canada is the chair of the Screening and Early Detection Committee. The Committee is focused on climate change, specifically air pollution and lung cancer, and published the **Air Pollution and Lung Cancer – The IASLC Position Statement** and encouraged global policy makers to include LDCT screening for lung cancer in national screening recommendations in the **EU Call for Evidence: Cancer Screening Recommendation Update** and will be publishing a white paper in 2023 focused on LDCT.



**DR. ELLA KAZEROONI:**  
**LUNG CANCER SCREENING SAVES LIVES**



Learn more about the staging committee under the scientific project on page 8.

## Staging & Prognostic Factors Committee

The Staging & Prognostic Factors Committee works to study and improve the current staging system for lung cancer, as well as for thymic, esophageal cancers, and mesothelioma. Staging lung cancer and other thoracic malignancies accurately is critical in deciding treatment regimens and ensuring the best standardized care for patients worldwide. For the past 20 years, the committee has been instrumental in producing evidence-based recommendations for the TNM Classification for Thoracic Cancers, published by the Union for International Cancer Control (UICC) and the American Joint Council on Cancer (AJCC). Committee members are currently working to develop recommendations for the ninth edition of TNM. **Dr. Hisao Asamura** of Keio University School of Medicine in Japan chairs the committee.

## Tobacco Control and Smoking Cessation Committee

The Tobacco Control and Smoking Cessation Committee seeks to provide advice and direction to activities and initiatives that the association should engage in to reduce the use of tobacco worldwide. The committee ensures that IASLC addresses the needs of practitioners seeking to help their patients stop tobacco use and recommends actions to contribute to international and local/national efforts in tobacco control initiatives and interventions. In 2022, the Tobacco Control and Cessation Committee updated the **IASLC Position Statement on Tobacco Cessation After a Cancer Diagnosis, signed onto multiple tobacco-related initiatives**, and worked with the IASLC Board of Directors to create two awards at WCLC 2023 to incentivize submissions on tobacco control and smoking cessation. The committee is chaired by **Dr. Bill Evans** of McMaster University in Canada.



# PATIENT ADVOCACY

Advances in the early detection of lung cancer, care of patients living with lung cancer, and novel treatment options have experienced phenomenal growth over the past decade. The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the lung cancer community and to the organization. We value inclusivity, and we hope to increase the pace of knowledge sharing and advancements in care by offering the patient advocate audience opportunities to:

- Attend conferences;
- Form relationships with researchers and care providers;
- Lend their voices, sitting side-by-side with researchers and members of the care team; and
- Share their perspectives and experiences.

## IASLC Supportive Training for Advocates on Research & Science (STARS)

The IASLC STARS program aims to increase the number of patient research advocates (PRAs) equipped to provide accurate scientific translation in their online or real-life groups for patients with lung cancer and their caregivers and to provide the patient perspective for lung cancer research and policy.



Research advocates (PRAs) are volunteers with a personal connection to lung cancer who are passionate about helping research translate into meaningful outcomes for patients and their families. The 2022 STARS program focused on

supporting STARS alumni by providing education in their areas of interest in research advocacy. PRAs participated in the program virtually throughout the year, with in-person networking opportunities at WCLC 2022, including an expert-led poster walk.

## PATIENT RESEARCH ADVOCATES



Laura Book  
USA



Lily Briggs  
USA



Sarah Christ  
USA



Diane Colton  
CANADA



Terri Conneran  
USA



Seamus Cotter  
IRELAND



Caleb Egwuenu  
NIGERIA



Shelly Engfer-Triebenbach  
USA



Tiffany Fagnani  
USA



Laura Greco  
USA



Tomma Hargraves  
USA



Lily Huang  
NEW ZEALAND



Leslie LaChance  
USA



Kimberly Lester  
USA



Nabanita Mandal  
INDIA

## PATIENT RESEARCH ADVOCATES



Susan McCullough  
AUSTRALIA



Anita McGrath  
AUSTRALIA



Jacquelyn Nixon  
USA



Stella O'Brien  
UNITED KINGDOM



Korina Pateli-Bell  
GREECE



Angus Pratt  
CANADA



Andrea Redway  
CANADA



Mike Smith  
USA



Baerbel Soehlke  
GERMANY



Debra Violette  
USA



Tom Wood  
AUSTRALIA



Christine Q Wu  
CANADA



Wayne Yeung  
USA

**STARS was developed by the IASLC in collaboration with lung cancer research advocates and patient advocacy nonprofits. In 2022, we appreciate our continued partnership with the Research Advocacy Network.**



**HEAR FROM PATIENT RESEARCH  
ADVOCATES & MENTORS ABOUT  
THEIR EXPERIENCE DURING THE  
IASLC STARS PROGRAM.**

### THANK YOU TO OUR 2022 SPONSORS



**North America Regional Winner —  
Baptist Cancer Center, Memphis, TN**

**Dr. Raymond Osarogiagbon, Medical Oncologist,  
Lead Nominee**

*“The entire team was always compassionate, professional, and offered me hope for a cure. Dr. Osarogiagbon was very understanding, gave me the facts, and hope for the future. He said that they will always take care of me. I never felt rushed. I did have good and bad days. But the team got me through it.”*

*– Marge Smith, patient and nominator for the North America team*

**Latin America Regional Winner —  
Instituto Nacional del Tórax,  
Providencia, Chile**

**Dra. María Paz Saavedra, Pneumologist Lung  
Cancer Department, Lead Nominee**

*“My mother’s medical oncologist and the entire team explained (the situation to) us (without) any doubt. This happened all the time with an excellent disposition. These included: sharing with me support group information, and very helpful information on workshops with psychologists and oncologists, and also, activities with the palliative care team,”*

*– Loreto Aguinaga Cordova, a family member and caregiver who nominated the Latin American team*

**Asia/ROW Regional Winner —  
Shanghai Pulmonary Hospital Affiliated  
to Tongji University, Shanghai, China**

**Dr. Caicun Zhou, Medical Oncologist,  
Lead Nominee**

*“They are a very professional team with rich experience and enough patience to get to know patients one-on-one and tell them how to face cancer. Unlike some doctors, they are very concerned about the mental health of their patients and often tell their patients that a good attitude is the first step in overcoming the disease. Rather than forcing the patient to do what they do, they give the patient choices that are often the best for the patient.”*

*– Weiran (Cici) Cao, caregiver and nominator of the Asia/ROW team*



**CANCER CARE TEAMS FROM NORTH AMERICA, LATIN AMERICA, AND ASIA ARE RECOGNIZED FOR THEIR EXEMPLARY CARE.**

# IASLC CANCER CARE TEAM AWARD

The IASLC Cancer Care Team Award is a prestigious award honoring and recognizing outstanding patient care served by multidisciplinary teams working together. Nominations are accepted from all over the world by individual patients with lung cancer and/or their caregivers/care partners. The IASLC is proud to honor the following winning teams of the 2022 IASLC Cancer Care Team Award:



North American Recipient: Baptist Cancer Center, Memphis, Tennessee



Latin American Recipient: Instituto Nacional del Tórax, Providencia, Chile



Asia/ROW Recipient: Shanghai Pulmonary Hospital, Affiliated to Tongji University, Shanghai, China

# CORPORATE RELATIONS

With the addition of new staff, IASLC implemented a relationship-driven corporate fundraising program. This included monthly calls with partners and in-depth meetings at multiple conferences. The team surpassed fundraising goals by strengthening partnerships, expanding the sponsorship portfolio, and developing innovative opportunities to create value both for the IASLC and its partners.

In addition to our meeting and event opportunities, we also offered specialized partnerships to support the development of IASLC resources, programs, scientific projects, and more.

We would like to extend a sincere thank you to the top sponsors of 2022.

abbvie

AMGEN®  
Oncology

AstraZeneca 



 Bristol Myers Squibb™

 Daiichi-Sankyo

EMD  
SERONO

Genentech  
*A Member of the Roche Group*

Janssen  | PHARMACEUTICAL COMPANIES OF  
*Johnson & Johnson*

 Jazz Pharmaceuticals.

*Lilly*

 MERCK

MIRATI  
THERAPEUTICS

 NOVARTIS

 Pfizer

REGENERON®



sanofi

 Takeda

To explore all the opportunities to engage with the IASLC,  
please contact us at [corporaterelations@iaslc.org](mailto:corporaterelations@iaslc.org).

**“It is my pleasure to pledge a contribution of up to \$10,000 in support of this unique international organization that casts a wide net to conquer thoracic malignancies worldwide.”**

– Dr. David Gandara

During WCLC 2022, Dr. David Gandara generously announced a dollar-for-dollar donation match of up to \$10,000 for all donations received during the conference. Dr. Gandara’s generosity encouraged attendees to support research grants that will help conquer lung cancer worldwide. Although we fell just short of the \$10,000 goal, the Foundation is very grateful for the \$9,685 raised from the challenge.



**\$13+ million**

has been given to

**LUNG CANCER RESEARCH**

and that number is on the rise!

# INTERNATIONAL LUNG CANCER FOUNDATION



Despite advances in research and early detection that are creating better outcomes and hope for lung cancer patients and their families, lung cancer claims more lives each year than breast, colon, and prostate cancers combined. Yet lung cancer receives disproportionately less government research funding per cancer death than other types of cancer. This makes the need for private support of lung cancer research, like that provided to the IASLC Foundation, LLC, critical.

Donations from patients, caregivers, other individuals, as well as from our organizational and corporate partners, directly fund our Research Grants Program—a global education initiative funding fellows and young investigators undertaking innovative research to eradicate lung cancer and other thoracic malignancies.

## Gifts from the Estate of Dr. Adi Gazdar

The Foundation is profoundly grateful to have been named as a beneficiary of the estate of Dr. Adi Gazdar. Dr. Adi Gazdar’s wife, Celia, passed away on March 23, 2022, causing the execution of the estate. In 2022, the Foundation received just over \$1.15 million from the Gazdars’ estate.

A longtime member and former Board Member of the IASLC, Dr. Gazdar bequeathed to the IASLC/ILCF all license fees and royalties for the biological reagents (cell lines) that he generated while employed by the University of Texas Southwest Medical Center and the National Institutes of Health. This bequest will generate approximately \$65,000 in ongoing annual revenue for the Foundation. Dr. Gazdar also bequeathed a lump sum of \$500,000 as well as “all the rest and residue” of his estate. Dr. Gazdar’s will stipulates that the funds be used “for fellowships in lung cancer research in my name.” In honor of Dr. Gazdar and his exceptional gift, the Foundation’s Fellowship Grant will hereafter be named the “Adi F. Gazdar Fellowship Grant.”

## 2022 Individual Donations

The ILCF had another successful fundraising year in 2022, receiving \$78,426 in individual donations. We thank each individual who donated to support lung cancer research in 2022. Please [click here](#) for the full list of our 2022 donors.

## 2022 Research Grants Program

In 2022, the Foundation awarded 14 Research Grants totaling \$850,000. This year’s grant recipients represent another diverse group of early-career researchers from around the world. The ILCF Research Grants are made possible by donations from individual donors, foundation partners, and pharmaceutical companies and foundations.

### 2022 Foundation Partner



### 2022 Funding Partners

The 2022 ILCF Research Grants Program is funded by grants from:



## 2022 YOUNG INVESTIGATOR GRANT RECIPIENTS

**Dr. Lawson Eng**, Princess Margaret Cancer Centre, Canada  
**Project Title:** Understanding the Impact of Age and Frailty on Immune Checkpoint Inhibitor (ICI) Outcomes in Lung Cancer Patients



**Dr. Molly Siu Ching Li**, The Chinese University of Hong Kong, Hong Kong  
**Project Title:** Elucidation of Intratumoral Heterogeneity of ALK-rearranged Non-Small Cell Lung Cancer and its Clinical Impact



**Dr. Colin Lindsay**, The Christie NHS Foundation Trust, United Kingdom  
**Project Title:** Functional Examination of NF1 Co-Mutation in KRAS Codon 13 Mutated Non-Small Cell Lung Cancer



**Dr. Zsolt Megyesfalvi**, National Koranyi Institute of Pulmonology, Hungary  
**Project Title:** Identification of Subtype-Specific Small Cell Lung Cancer Biomarkers with Multiomic Approaches



**Dr. Stephanie Saw**, National Cancer Centre Singapore, Singapore  
**Project Title:** PROgnostic Value of PD-L1 Score Post-Surgery in EGFR-Mutated Lung Cancer (PROSPER)



**Dr. Gavitt Woodard**, Yale University School of Medicine, United States  
**Project Title:** Gene Expression and T-cell Dysfunction in Enlarging Semi-Solid Lung Adenocarcinomas



## 2022 LCFA/BMS/ILCF DISPARITIES IN CLINICAL ONCOLOGY RESEARCH GRANTS

**Dr. Jonathan Villena-Vargas**, Weill Cornell Medicine, United States  
**Project Title:** Characterizing T-Cell PD-1 Response in the Tumor Draining Lymph Nodes of Early-Stage NSCLC Patients



## 2022 FELLOWSHIP GRANT RECIPIENTS

**Dr. Adithya Balasubramanian**, Walter & Eliza Hall of Medical Research (WEHI), University of Melbourne, Australia  
**Project Title:** Targeting Immune Resistance Mechanisms to Enhance Anti-Tumour Immunity in Non-Small Cell Lung Cancer



**Dr. Diego Serrano**, Universidad de Navarra, Spain  
**Project Title:** Development of Novel Strategies to Fight Locoregional Recurrence in Lung Cancer Based on the Discovery of Radiosensibilizing Therapies



**Dr. Ting-Yu Shih**, Boston University, United States  
**Project Title:** Treating Lung Adenocarcinoma with a Tumor-Targeting Therapy



**Dr. Lavanya Sivapalan**, Sidney Kimmel Cancer Center, Johns Hopkins University, United States  
**Project Title:** Evolutionary Trajectories of Tumor and the Tumor Microenvironment for Early-Stage Non-Small Cell Lung Cancer in the Context of Neoadjuvant Immunotherapy



**Dr. Amila Suraweera**, Queensland University of Technology, Australia  
**Project Title:** Development of a Novel Therapeutic for the Treatment of Non-Small Cell Lung Cancer



**Dr. Marco Tagliamento**, Gustave Roussy, France  
**Project Title:** The CHIC Study (Clonal Hematopoiesis In Lung Cancer)



**Dr. Elena Torreggiani**, University of Ferrara, Italy  
**Project Title:** Dissecting the Role of Alpha-1 Antitrypsin in Malignant Pleural Mesothelioma Onset and Progression



## ILCF BOARD OF DIRECTORS



**David Carbone, MD, PhD**  
 Chair  
 USA



**David Gandara, MD**  
 Vice Chair  
 USA



**Tetsuya Mitsudomi, MD, PhD**  
 IASLC Past-President  
 JAPAN



**Lauren Fisher**  
 Member  
 USA



**Karen Kelly, MD**  
 CEO  
 USA  
*ex-officio, non-voting*

Also in 2022, the ILCF Board of Directors and the IASLC Board of Directors worked with a team of consultants to help determine the best way for the Foundation and its Research Grants Program to thrive now and in the future. The ILCF had operated as a separate legal entity, with a separate tax identification number, for several years. Beginning in 2023, the Research Grants Program will transition from the ILCF to the IASLC Foundation, LLC, a wholly-owned entity of the IASLC. Contributions to IASLC Foundation, LLC are treated as charitable contributions to a branch or division of IASLC. This change will provide streamlined operations and increased brand recognition to the Research Grants Program.

# 2022 ILCF DONORS

Donors are listed alphabetically by first/given name

## TOP DONORS

Estate of Dr. Adi F. Gazdar  
(\$1,152,500)  
David and Diane Gandara  
(\$10,000)  
Be Your Possible, Inc.  
(\$4,880)

## INDIVIDUAL AND CORPORATE DONORS

### \$1,000-\$2,999

Antoinette Wozniak  
David Carbone  
Greg Galanos  
Jennifer Lamont  
Karen Kelly  
Lecia Sequist  
REIOP, Inc.  
Roy Herbst

### \$500-\$999

Boris Borisov  
Brendon Stiles  
Erin Fitzgerald  
Heather Wakelee  
Jack Ruckdeschel  
Lauren Fisher  
Lizza Hendriks  
Maggie Connolly  
Nadine Housri  
Natasha Leighl

### \$100-\$499

Aki Kobayashi  
Alice Chen  
Andre Moreira  
Andrea Bezjak  
Andrea Borondy Kitts  
Angel Lopez-Galindo  
Angela M Takano  
Anita Archwamety  
Anne Traynor  
Art Mallette  
Balazs Halmos  
Benjamin Solomon  
Benson Vuong  
Betty Tong  
Bruce Dunbar  
Caicun Zhou  
Charles M Rudin

Corey Langer  
Daniel Sterman  
David Ball  
David Gierada  
David Harpole  
David LeDuc  
David Shames  
David Stewart  
Ebenezer Kio  
Emanuel Citgez  
Emily Stone  
Eric Bernicker  
Eric Sbar  
Eric Vallieres  
Erik Thunnissen  
Etsuo Fujita  
Eugene Paschold  
Eugene Vissers  
Eungbae Lee  
Ferdinando Cerciello  
Fiona Hegi-Johnson  
Fred Hirsch  
Glenn Lukos Associates, Inc.  
Gregory M.M. Videtic  
Gregory Raber  
Helmut Prosch  
Hiran Fernando  
Hiromasa Yamamoto  
Hossein Borghaei  
Jacques Mascaro  
James Chih-Hsin Yang  
James Jett  
Janet Piorko  
Jasleen Pannu  
Jason Porter  
Jhanelle Gray  
Joel Neal  
John Hallick  
John Minna  
Joo-Hang Kim  
Julie Brahmer  
Jyoti Patel  
Karen Reckamp  
Katherine Sugarman  
Kathryn Mileham  
Kazuhiko Shibata  
Keunchil Park  
Konstantinos Leventakos  
Leora Horn  
Li Xu  
Lisa Biggs

Louis Geeraerts  
Luis Raez  
Luka Brcic  
Lynn & Greg Fricke  
Lyudmila Bazhenova  
Magnus Ulimoen  
Makenzi Evangelist  
Mallory Benjamin  
Maria Amelia Almeida  
Martin Edelman  
Mary Jo Fidler  
Masahiro Tsuboi  
Matthew Yeingst  
Matthijs Oudkerk  
Mia Grane Jawdat  
Michael Gieske  
Michelle Brockman  
Milada Zemanova  
Ming Tsao  
Misako Nagasaka  
Miyako Satouchi  
Neal Ready  
Nichol Miller  
Nico Van Zandwijk  
Paul Hesketh  
Paul Van Schil  
Paul Walker  
Qinghua Zhou  
Rachel Sanborn  
Rajwanth Veluswamy  
Ricardo Salgado  
Robert Pirker  
Sergio Santillana  
Sherry Baskerville-Bridges  
Stephen Lam  
Taofeek Owonikoko  
Ted Blank  
Theresa LaVallee  
Todd Sanft  
Tom John  
Turja Chakrabarti  
Umberto Malapelle  
Veronica Buckley  
Vito Quaranta  
Wade Iams  
William Travis  
William Walsh  
Yasushi Yatabe  
Yidan Qin  
Young Tae Kim

### \$50-\$99

Aaron Paolotto  
Alecsandra Anca Tudor  
Alfredo Lopez  
Andrew Eagle  
Angus Pratt  
Antonio Calles Blanco  
Brian E Persing  
Caitlin Enright  
Calvin Sze Hang Ng  
Carlos Ferreira  
Carol Peitzsch  
Chi-Fu Jeff Yang  
Chiho Nakashima  
Clarissa Baldotto  
Desiree Hao  
Dhruv Bansal  
Dwight Owen  
Eric Santoni-Rugiu  
Evan Osmundson  
Georges Decker  
Gerard J Fitzmaurice  
Giovanni Selvaggi  
Greg Otterson  
Harvey Pass  
Heidi Mulqueen  
Helano Freitas  
Henriette Klein  
Hideo Tsuchiya  
Hiran Chrisantha Fernando  
Ida Meister  
Ina Nordman  
Jae Heun Chung  
Jason Porter  
Jeffrey Bradley  
Jennifer Wing  
Ji Yeon Kwon  
Jimmie Ward  
John Ferguson  
John Mccann  
John Skadow  
Josh Sonett  
Juan Carlos Vazquez Limon  
Judy Johnson  
Jules Derks  
Katharine Rendle  
Kathryn Engelhardt  
Katie Redfield  
Kentaro Nakagawa  
Kert Sabbath

**\$50-\$199** CONTINUED

Kevin Franks  
Klaus L Irion  
Lana Schumacher  
Lee Krug  
Louis Denis  
Marcia Horn  
Marclesson Alves  
Margot Lehman  
Matthew Steliga  
Matthijs F.M. Van Oosterhout  
Melanie Janning  
Meng Welliver  
Meng Welliver  
Michael Limbird  
Michelyn Camen  
Morten Quist  
Mya Sadler  
Myung-Ju Ahn  
Nan Wu  
Nicolaus Andratschke  
Osarenren Ogbeide  
Pan Zheng  
Patricia Fisher  
Patrizia Froesch  
Paul Van Houtte  
Paul Wheatley-Price  
Peggy Dennis  
Qiaofang Chen  
RhythmLink  
Robert Stirling  
Sara Pilotto  
Shirish Gadgeel  
Shunichi Sugawara  
Sjaak Burgers  
Sonal Harchandani  
Spellman Gibbons Polizzi  
Truncale & Trentacoste, LLP  
Srikumar Chellappan  
Stephen Liu  
Stephen Wang  
Susan Harden  
Susan Scott  
Suzanne Dahlberg  
Tara Herrmann  
Tessa Baxter  
Tirrell Johnson  
Toni Enright  
Viktorija Shtonda  
Virginia Spadoni  
Wilfried E.E. Eberhardt  
Wolfgang Deschka

Yi-Long Wu  
Yutaka Hatanaka  
**UP TO \$49**  
Abdelali (Ali) Majdi  
Ahmad Mansour  
Akif Turna  
Alberto Traverso  
Alessandro Mariani  
Alessandro Russo  
Alexei Kamenev  
Alfredo Aguilar Cartagena  
Alicia Isabell Tans  
Amy Grove  
Andre Spring  
Andrea Riccardo Filippi  
Andrea Veatch  
Andrew Paetow  
Andrew Piper  
Andrzej Milewski  
Angela De Palma  
Angela Gaerlan-Tagle  
Angela Parikh  
Anh Tuan Tran  
Anke Dunitza  
Anna Fritsch  
Anna Renkert  
Arvind Kumar  
Ashley Woolweaver  
Asrar Abdullah Alahmadi  
Asuka Okada  
Aurora O'Brate  
Avanthi Ragam  
Bailey Creamer  
Barbara Gitlitz  
Barbara Pastorello  
Berhanu Tsige  
Bibhusal Thapa  
Biche Osong  
Bin-Chi Liao  
Biniam Kidane  
Birgit Weynand  
Bojana Pajk  
Brianna Lau  
Bubse Na  
Cameron Block  
Chaichana Chantharakhit  
Chang-Min Choi  
Charlene Knutilla  
Charu Aggarwal  
Chere Cofer  
Chia-I Huang

Chris Schneider  
Christian Rolfo  
Christie Allen  
Chulaporn Jatuparisuthi  
Clarissa Mathias  
Cristina Fernandez Ferradas  
Dana Deshet  
Daniel Spakowicz  
David Domsic  
David Hwang  
Dawn Colburn  
Debra Dyer  
Deepti Behl  
Devon Toliver  
Diane Colton  
Diane Legg  
Diego Diaz  
Dragana Jovanovic  
Edith Marom  
Eduardo Medeiros  
Edwin Javier Crespo Martinez  
Edyta Maria Urbanska  
Eldsamira Mascarenhas  
Eloa Brabo  
Emanuela Taioli  
Emi Bossio Bell  
Emil Kuriakose  
Emily Venanzi  
Erna Kusumawardhani  
Esra Akbay  
Farrah Khan  
Fiona Macdonald  
Firas Said  
Flavia Zarcula  
Florian Dr. LÄnger  
Francisco Orlandi  
Francoise Galateau-Salle  
Georg Langs  
Gerard Hanna  
Gerard Walls  
Gilberto Castro Junior  
Gregory Otterson  
Haluk Tezcan  
Han Pil Lee  
Hidetoshi Hayashi  
Hisao Asamura  
Hisashi Saji  
Hua Cheng  
Hyeok Sang Woo  
Hyojin Kim  
Inga Lennes  
Ivan Mattie

Jacqui Frowen  
Jaime Fernandez  
Jair Bar  
Jan Mazotti  
Jan Nyman  
Jana Doyle  
Jennifer Aversano  
Jennifer Wheeley  
Jianjun Zhang  
Jiwan Kwak  
Joachim Aerts  
Joana Rei  
Joao Alessi  
Joao Paulo Villalba  
John Liming  
Jonathan Clark  
Jonathan Goldman  
Jonathan Spicer  
Jonathon Herbst  
Jose Corona Cruz  
Joseph Elia  
Joseph Steward  
Julia Judd  
Julien Vincenten  
Junichi Shimizu  
Junyuan Wang  
Justin Gainor  
Justin Holko  
Jyoti Patel  
Kalliopi Athanasoulis  
Katarzyna Nej Wolosiak  
Kathleen Gambino  
Kathy Gately  
Katie Maher  
Katsuyuki Kiura  
Keiju Aokage  
Kellie Giles  
Kelly Wright  
Ken Harrell  
Ken Uchibori  
Kevin Chua  
Khaled Kamal  
Ki Hyeong Lee  
Kristen Cordova  
Kwun Fong  
LaKedia Banks  
Larry Stone  
Lavinia Magee  
Leena Elizabeth Joseph  
Leonardo Roeder  
Leslie Lachance  
Lilian Faroni

*Donors are listed alphabetically by first/given name*

**UP TO \$49** CONTINUED

- Lillian Leigh  
Lindsay Pastore  
Lindsay Thompson  
Lisa Cruz  
Louise Nott  
Lucas Vitzthum  
Lucia M Viola  
Luigi Ventura  
Luis Alberto Corrales Rodriguez  
Lynn Sametz  
Marc de Perrot  
Marcelo Corassa  
Maria Gitto  
Maria Lucia Reale  
Maria Werner-Wasik  
Mariana Petaccia de Macedo  
Marianne Davies  
Marjorie Deninger  
Mark Woodcock  
Mary Duffy  
Mary Todd  
Maryann Bradley  
Masaya Yotsukura  
Matt Presby  
Matthew Belbasis  
Matthew Smeltzer  
Mauricio Pimentel  
Maya Khalil  
Megan Daly  
Melissa Johnson  
Melissa Neumann  
Michael Boyer  
Michaela Kirschner  
Miltiadis Krokidis  
Miriam Ceraolo  
Nagashree Seetharamu  
Nahida Islam  
Naoko Shiraiwa  
Nelson Ang
- Nguyen Son Lam  
Nina Helbekkmo  
Noelia Aybar  
Oleg Kshivets  
Olga Valdman  
Oliver Illini  
Onyx Bengston  
O’Ryan Jackson  
Paul Cockrum  
Paula Ugalde  
Philippe Lebel  
Pietro Bertoglio  
Ping Hu  
Prabhu Prasad  
Rachelle Michie  
Raghav Chandra  
Rebecca Bunn  
Reina Misono  
Reiri Onodera  
Renaud Whittom  
Renee Parker  
Renelle Myers  
Rex Yung  
Robert Kratzke  
Rodrigo Sagastegui  
Roman Yelensky  
Roselle De Guzman  
Ross Hair  
Ryan Gentzler  
Sameera Kumar  
Samina Park  
Sanford Hoffman  
Sang-Yoon Lee  
Sarah Wang  
Sarah Weaver  
Satoru Miura  
Satoshi Hara  
Satoshi Muto  
Satoshi Shiono  
Sayeda Yasmin-Karim
- Seamus Cotter  
Sebastian Peitzsch  
Selda Samakoglu  
Shanda Blackmon  
Shannon Zhang  
Shawn Butler  
Shirley Hughes  
Shota Nakamura  
Signe Fransen  
Simon Ekman  
Simona Borilova  
Soe Aung  
Sofia Baka  
Sonam Puri  
Spasenija Savic Prince  
Stefan Watzka  
Stefano Cafarotti  
Stephan Soder  
Stephanie Vakaljan  
Sujay Shah  
Suman Shrestha  
Sunhee Malinowski  
Süreyya Sarihan  
Suyog Jain  
Sylvie Gaudet  
Takaaki Sasaki  
Tamas Molnar  
Tanaka Fumihiro  
Tania Alfaro  
Taysser Sowley  
Temple of Israel Religious School  
Teresa Garcia-Manrique  
Thomas Amoah  
Tiffany English  
Tina Cascone  
Tindara Franchina  
Todd Buchanan  
Tom Wood  
Tomma Hargraves
- Tomohide Tamura  
Toshiyuki Harada  
Trevor Williams  
Veni Ezhil  
Vincent Fallet  
Vinod Sharma  
Viviane Alencar  
Vladimira Horvat  
Vun-Sin Lim  
Wei Wang  
Weiqing Wang  
Wendy Cooper  
Windfield Tan  
Xiaokui Mo  
Yao-Ming Shih  
Yeon Wook Kim  
Yeonsil Kim  
Yewande Pearse  
Yoshitaka Sekido  
Youjin Oh  
Younes El Founini  
Yuki Matsumura  
Yukihiro Yoshida  
Yvette Thomas-Fogg  
Zach Woolweaver  
Zhimin Zeng

# FINANCIALS

## DECEMBER 31

	2022 (Unaudited)	2021 (Audited)
<b>Program Revenues</b>	\$17,725,947	\$14,297,877
<b>Membership Revenues</b>	\$673,597	\$633,507
<b>Total Revenues</b>	\$18,399,544	\$14,931,384

<b>Direct Program Expenses</b>	\$10,767,546	\$9,576,707
<b>G&amp;A Expenses</b>	\$6,257,671	\$5,496,829
<b>Total Expenses</b>	\$17,025,217	\$15,073,536


<b>Operating Surplus</b>	\$1,374,327	(\$142,152)
--------------------------	-------------	-------------

<b>Other Income (Loss)/Expense</b>	(\$1,410,258)	\$1,171,478
------------------------------------	---------------	-------------

## DECEMBER 31

	2022 (Unaudited)	2021 (Audited)
<b>Assets</b>	\$20,795,872	\$21,306,201
<b>Liabilities</b>	\$6,374,917	\$6,849,315
<b>Net Assets</b>	\$14,420,955	\$14,456,886

## REVENUE BY TYPE



# IASLC BOARD OF DIRECTORS

## EXECUTIVE COMMITTEE



**Heather Wakelee, MD**  
President  
United States



**Paul Van Schil, MD, PhD**  
President-Elect  
Belgium



**Tetsuya Mitsudomi, MD, PhD**  
Past-President  
Japan



**Andrea Bezzak, MD, FRCPC, MSc**  
Secretary  
Canada



**Erik Thunnissen, MD**  
Treasurer  
Netherlands



**Karen Kelly, MD**  
CEO  
United States

## BOARD MEMBERS



**Joachim Aerts, MD, PhD**  
Netherlands



**Carlos Gil Ferreira, MD, PhD**  
Brazil



**Jhanelle Gray, MD**  
United States



**Roy Herbst, MD, PhD**  
United States



**Young Tae Kim, MD, PhD**  
South Korea



**Morten Quist, PT, PhD, MSc, HS**  
Denmark



**Lecia Sequist, MD, MPH**  
United States



**Ming-Sound Tsao, MD, FRCPC**  
Canada



**Paula Ugalde, MD**  
United States



**Caicun Zhou, MD, PhD**  
China

# IASLC STAFF

## EXECUTIVE TEAM



**Karen Kelly, MD**  
Chief Executive Officer



**J. Michael Hoehn, CAE**  
Chief Operating Officer



**John Skadow**  
Chief Financial Officer



**Matt Yeingst, CFRE**  
Chief Development Officer

## STAFF



**Tessa Baxter**  
ILC Foundation  
Coordinator,  
Project Manager



**Becky Bunn**  
Senior Advisor,  
Scientific Relations



**Mya Burns**  
Associate Director,  
Conferences



**Casey Connolly**  
Scientific Affairs  
Specialist



**Bailey Creamer**  
Editorial Assistant



**Kathy Doherty**  
Director,  
Human Resources



**Wanda Folsom**  
Education Manager



**Rory Graham**  
Web Content  
Administrator



**Ken Harrell**  
Member Records  
Administrator



**Kelsey Hecker**  
Conference  
Coordinator



**Kelly Heemsbergen**  
Conference Manager



**O'Ryan Jackson**  
Administrative  
Assistant



**Vun-Sin Lim, PhD**  
Editorial Consultant,  
*JTO Clinical and  
Research Report*



**Sara Lindsey Patton**  
Patient Advocacy Specialist



**Katie Maher**  
Member Experience  
Specialist

## STAFF CONTINUED



**Sunhee Malinowski**  
Accounting Manager



**Jan Mazotti**  
Associate Director,  
Marketing &  
Communications



**Karen Muth**  
Executive Assistant  
and Board Liaison



**Kelly Nevins**  
Associate Director,  
Education



**Rodrigo Sagastegui**  
Marketing Specialist



**Kelsey Wood**  
Associate Director,  
Member Experience



**Kelly Wright**  
Member Experience  
Coordinator



**Murry Wynes, PhD**  
Senior Advisor,  
Scientific Affairs



**Kexin Yu**  
Accountant



**Flavia Zarcula**  
Corporate Relations Manager

## CONNECT WITH US



**CONQUERING THORACIC CANCERS WORLDWIDE**



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER  
Conquering Thoracic Cancers Worldwide